News >

Brentuximab Vedotin Improves Survival in Frontline CD30+ PTCL

Jason M. Broderick @jasoncology
Published: Monday, Oct 01, 2018

Clay Siegall, PhD

Clay Siegall, PhD
Combining brentuximab vedotin (Adcetris) with frontline chemotherapy led to a statistically significant improvement in progression-free and overall survival (PFS/OS) in patients with CD30-expressing peripheral T-cell lymphoma (PTCL), according to topline results from the phase III ECHELON-2 trial.

 
“We are excited about the groundbreaking results of the phase III ECHELON-2 clinical trial, which demonstrated Adcetris in combination with chemotherapy significantly improved treatment outcomes for adult patients with previously untreated CD30-expressing PTCL compared with the current standard of care (CHOP). We’d like to thank the many investigators and patients who participated in this study and contributed to this significant milestone for the PTCL community. We look forward to presenting results at the ASH annual meeting in December and intend to submit a supplemental biologics license application to the FDA for approval in this setting in the near future,” added Siegall.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x